**4.4 Interests in long-term continuous glucose monitoring in persons on insulin pumps-one centre experience (2006–2012)**

**The purpose** of this prospective study [57] was to assess the real patient´s interest in routine use of transcutaneous sensors related to hypothetic optimum state of "always on CGM".

**Methods and results:** In the course of 7 years (from 2006 to 2012), the sensor augmentation of Continuous Subcutaneous Insulin Infusion (CSII) was repeatedly offered free of charge to all PWD on pumps (n=123) attending the regular check-ups supported by Carelink Personal software. The CGM was accepted for a variable number of days by 63 (51%) of them. The real percentage of time spent on CGM shows the present study (**Table 3**).

SPSS v 15.0, SPSS Inc., Chicago, IL, was used for statistical analysis. P < 0.05 was considered significant. Fisher´s exact test and Mann–Whitney U test revealed no significant differences in number of PWD, duration of diabetes, duration of CSII, duration of offer of CGM, total number of days with real use of CGM and rates of real use of CGM compared between PWD1 vs. PWD2 and men vs. women, except the age of PWD1 vs. PWD2 at start of CSII (P = 0.0001). The interests of PWD on CGM augmented CSII and their real-life conditions resulted in median of up to 14.1 % time

*Intensive Management of Type 1 Diabetes in Adults: One Centre Experience 1970–2022 DOI: http://dx.doi.org/10.5772/intechopen.108032*


**Table 3.**

*Characteristics of PWD on insulin pumps and their interest in sensor-augmented CSII (median, percentile 25 and 75).*

of CGM use. So, having made available sensors and CGM education for unlimited time for all 123 PWD on insulin pumps in our centre, their attitudes and motivation remained to be adopted.
